Not finding it? Sign in to also search OpenAlex live.
-
OX40 agonism enhances efficacy of PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum2021 bioRxiv (Cold Spring Harbor Laboratory) preprint Medicine Cancer Immunotherapy and Biomarkers Open access
Guillaume Beyrend, Tetje Cornelia van der Sluis, Esmé T.I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, +16 more
0citations -
155eP Real-world effectiveness of first-line nivolumab plus ipilimumab with chemotherapy in patients with non-small cell lung cancer with low PD-L1 tumor expression (Dutch NVALT-34 study)
Corina van den Hurk, Bas J.M. Peters, Dagmar T A Hiensch, Egbert Frederik Smit, Elisabeth A. Kastelijn, B.V. van Veggel, +4 more
0citations -
Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents2022 Journal of Nanobiotechnology article Medicine Radiopharmaceutical Chemistry and Applications Open access
Iris M. Hagemans, Peter J. Wierstra, Kas Steuten, Janneke D.M. Molkenboer‐Kuenen, Duco van Dalen, Martin ter Beest, +7 more
10citations -
IFN‐γ‐induced PD‐L1 expression on human melanocytes is impaired in vitiligo2021 Experimental Dermatology article Biochemistry, Genetics and Molecular Biology melanin and skin pigmentation Open access
Marcella Willemsen, Gabrielle Krebbers, Esther P.M. Tjin, Karin J. Willemsen, Alesha Louis, Veronique A. L. Konijn, +6 more
22citations -
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”2025 European Journal of Cancer article Medicine Cutaneous lymphoproliferative disorders research Open access
Rudolf Stadler, Gabriele Roccuzzo, Pablo Luis Ortiz-Romero, Martine Bagot, Pietro Quaglino, Emmanuella Guenova, +15 more
12citations -
Selektive Kupferchelation reduziert Tumorwachstum und PD-L1-Expression in einem immunkompetenten syngenen Mausmodell des Lungenkarzinoms2026 Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie article Medicine Cancer Immunotherapy and Biomarkers
B. Ohm, S. Andreoli, G. Meier Bürgisser, Katharina‐Susanne Spanaus, Christoph J. Fahrni, Wolfgang Jungraithmayr, +1 more
0citations -
(Pseudo)-neoadjuvuant Gemcitabine Based Chemotherapy with or without PD-L1-Immunecheckpoint Inhibitor versus Upfront Surgery in Locally Advanced Intrahepatic Cholangiocarcinoma – An International Multicenter Retrospective Cohort Study (NeoSurg-ICC)
C. Scholz, F. Bartsch, J. Mittler, T. Huber, S. Sliwinski, T. Hackert, +16 more
0citations -
Safety, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of AZD2936, a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-experienced advanced/metastatic non-small-cell lung cancer (NSCLC): First report of ARTEMIDE-01.2023 Journal of Clinical Oncology conference-abstract Medicine Cancer Immunotherapy and Biomarkers Open access
Kristoffer Staal Rohrberg, Mariana Brandão, Eduardo Castañón Álvarez, Enriqueta Felip, Eelke Hiddo Gort, T. Jeroen N. Hiltermann, +14 more
22citations -
PD-1 or CTLA-4 blockade promotes CD86-driven Treg responses upon radiotherapy of lymphocyte-depleted cancer in mice2024 Journal of Clinical Investigation article Medicine Cancer Immunotherapy and Biomarkers Open access
Elselien Frijlink, Douwe M. T. Bosma, Julia Busselaar, Thomas Battaglia, Mo D. Staal, Inge Verbrugge, +1 more
36citations -
Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy2021 Journal for ImmunoTherapy of Cancer article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Kim E. Kortekaas, Saskia J A M Santegoets, Liselotte Tas, Ilina Ehsan, Pornpimol Charoentong, Helena C. van Doorn, +3 more
28citations -
Abstract CT021: Preliminary clinical results of a therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with stage IV NSCLC2024 Cancer Research conference-abstract Immunology and Microbiology Immunotherapy and Immune Responses
Willemijn S.M.E. Theelen, Maurice Pérol, Kristof Cuppens, Ingel Demedts, Frank Borm, Bonne Biesma, +17 more
3citations -
STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancer2021 British Journal of Pharmacology article Immunology and Microbiology Immune cells in cancer Open access
Rômulo S. Cavalcante, Uta Ishikawa, Emanuell S. Silva, Arnóbio Antônio da Silva-Júnior, Aurigena Antunes de Araújo, Luis Javier Cruz, +2 more
73citations -
The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes2020 Cancer Cell article Medicine Cancer Immunotherapy and Biomarkers Open access cited by 3 patents
Floris F. Dammeijer, Mandy van Gulijk, Evalyn E.A.P. Mulder, Melanie M. Lukkes, Larissa Klaase, Thierry P. P. van den Bosch, +18 more
720citations -
878P Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Anthony H. Kong, Caroline Even, Begoña Aguilera, Marielle Klein Hesselink, Sonja Visscher, J.C. Park, +9 more
4citations